
Vijay Pande discusses launching the smaller, AI-native VZVC after leading a roughly $4 billion biotech practice at a16z. He argues that biology is moving from discovery toward engineering, while warning that costly clinical trials and fragmented data remain major barriers to AI-driven medicine.
1:36 PMTechCrunch